Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.52 |
| ▸ | HRH1 | P35367 | 4/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | DRD3 | P35462 | 2/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23915516 | 0.97 | MAPT (0.56) | MAPTPOLBABCB1ADRA1AHRH1 | |
| SCHEMBL23909085 | 0.94 | MAPT (0.58) | MAPTPOLBABCB1ADRA1AHRH1 | |
| SCHEMBL23915509 | 0.82 | SMN1; SMN2 (0.52) | MAPTABCB1ADRA1AHRH1ADRA1B | |
| SCHEMBL23914636 | 0.80 | SMN1; SMN2 (0.50) | MAPTPOLBABCB1ADRA1AHRH1 | |
| SCHEMBL23913685 | 0.79 | MAPT (0.64) | MAPTPOLBHRH1HRH3AKR1B1 | |
| SCHEMBL23914926 | 0.77 | MAPT (0.48) | MAPTPOLBSMN1; SMN2LMNAAKR1B1 | |
| SCHEMBL23909121 | 0.76 | NPC1 (0.47) | MAPTPOLBADRA1AHRH1ADRA1B | |
| SCHEMBL23915524 | 0.76 | MAPT (0.67) | MAPTPOLBAKR1B1TSHRKMT2A | |
| SCHEMBL23966505 | 0.74 | MAPT (0.43) | MAPTPOLBABCB1ADRA1AHRH1 | |
| SCHEMBL22721898 | 0.74 | ABCB1 (0.47) | ABCB1ADRA1AHRH1ADRA1BADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | MAPT 4876/4885POLB 3606/4885ABCB1 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.